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Aims To evaluate the diagnostic accuracy of cardiovascular magnetic resonance (CMR) imaging from a risk-stratification
and therapeutic-management perspective in patients with suspected cardiac tumours.
Methods and
results
Cardiovascular magnetic resonance exams of 41 consecutive patients (aged 61+14 years, 21 men) referred for
evaluation of a suspected cardiac mass were reviewed for tumour morphology and signal characteristics in various
unenhanced and contrast-enhanced sequences. Cardiovascular magnetic resonance-derived diagnosis and treatment
were compared with clinical outcome and histology in patients undergoing surgery or autopsy (n ¼ 20). In 18 of 41
patients, CMR excluded masses or reclassified them as normal variants; all were treated conservatively. In 23 of 41
patients, CMR diagnosed a neoplasm (14 ‘benign’, 8 ‘malignant’, and 1 ’equivocal’); 18 of these patients were operated
on, 2 managed conservatively, and 3 by palliation. During follow-up of 705 (inter-quartile range 303–1472) days, 13
patients died. No tumour-related deaths occurred in conservatively managed patients. Patients with a CMR-based
diagnosis and treatment of benign tumour had a similar survival as patients without detectable tumour. Compared
with histology, CMR correctly classified masses as ‘benign or malignant’ in 95% of the cases. Tumour perfusion, inva-
siveness, localization, and pericardial fluid were valuable to distinguish between malignant and benign tumours. Soft
tissue contrast and signal intensity patterns in various sequences were valuable for excluding neoplastic lesions and
helped to obtain tissue characterization at the histological level in selected tumour cases, respectively.
Conclusion Comprehensive CMR provides a confident risk-stratification and clinical-management tool in patients with suspected
tumours. Patients where CMR excludes tumours can be managed conservatively.
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Introduction
Cardiac tumours represent a rare but important cause of morbid-
ity and mortality.1–3 The therapeutic management of cardiac
masses differs fundamentally according to the nature of the
cardiac mass (neoplastic vs. non-neoplastic) and tumour type
(benign or malignant, primary or secondary), and furthermore
depends on clinical circumstances such as haemodynamic failure,
invasive growth, and metastatic spreading, which either prompt
for an intervention or rather make it irrational.1,2 Cardiac magnetic
resonance (CMR) imaging is considered the imaging modality of
choice for the assessment of cardiac masses.4 It permits high-
quality, multiplanar imaging of tumour morphology, tissue compo-
sition, and perfusion. Additional assets of CMR are its ability to
assess cardiac function, blood flow, and its large field of view
that allows visualization of the paracardiac structures and the
great vessels. Yet, studies demonstrating clinical advantages are
sparse. We conducted a retrospective study to evaluate the diag-
nostic accuracy of CMR from a patient-management perspective in
subjects with suspected cardiac or paracardiac tumours. For this
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purpose, CMR-derived tumour diagnosis was compared with the
histological findings of biopsy specimens in patients undergoing
surgery or autopsy. In patients declined from surgery based on
the CMR diagnosis, the predicted benign character and presumed
histology were compared with the clinical follow-up and outcome.
Methods
We retrospectively reviewed the CMR exams of all patients (n ¼ 41)
referred between January 2002 and August 2009 for the first evalu-
ation of a cardiac or paracardiac mass, detected or suspected at echo-
cardiography (n ¼ 39) or thoracic computed tomography (CT; n ¼ 2).
Patients with suspicion of thrombus were considered only if the refer-
ral question explicitly included tumour as differential diagnosis. Clinical
charts were reviewed for patient characteristics, disease symptoms,
medical history, and neoplastic disease established prior to initial echo-
cardiography and CMR. Data on disease course and outcome were
gathered from the time of CMR diagnosis until the date of study
closure (February 2010). Follow-up status was ascertained in all
patients by checking hospital records and by contacting the patients’
general practitioners with a short questionnaire on vital status, type
and date of major cardiovascular events, and last follow-up date. In
patients undergoing surgery or autopsy, intra-operative macroscopic
and histological findings were also recorded (Figure 1).
Cardiac magnetic resonance imaging
protocol
Cardiac magnetic resonance studies were performed on a 1.5 T system
equipped with a phased-array body coil (Sonata & Avanto, Siemens,
Erlangen, Germany). As a standard CMR protocol for the evaluation
of tumours and masses in our institution (‘cardiac tumour protocol’),
image sequences typically included axial T2-weighted turbo spin
echo sequences (T2-TSE) covering the entire thorax and breath-hold
segmented steady-state free precession cine imaging sequences in
four-chamber and short-axis views. T1-weighted turbo spin echo
sequences (T1-TSE) were targeted on the tumour mass. First-pass per-
fusion images through the lesion and myocardium were acquired by a
contrast-enhanced saturation recovery gradient-recalled echo
sequence after a bolus of 0.2 mL/kg (0.1 mmol/kg) gadobenate dime-
glumine (Multihance, Bracco, Mendrisio, Switzerland) infused at
4 mL/s and followed 10–15 min later by late gadolinium enhancement
(LGE) imaging using a breath-hold inversion-recovery gradient-echo
sequence. In addition, early contrast-enhanced T1-TSE, fat-saturated
T1-TSE, and/or black blood fat-saturated (triple inversion recovery)
T2 spin sequences were added if deemed necessary for further
tissue differentiation.5 All images were acquired under supervision of
an experienced (Level III) cardiologist and/or radiologist.
Evaluation and interpretation of cardiac
magnetic resonance images
Cardiac magnetic resonance images were retrospectively evaluated
during consensus reading sessions by at least one cardiologist and
one radiologist, to whom only the referral question was available.
Lesions were categorized as neoplastic or non-neoplastic lesions,
with the former further differentiated into benign or malignant
tumours and the latter into normal variants or non-neoplastic
masses, respectively. For suspected neoplastic lesions, a histological
diagnosis was postulated according to previously suggested criteria
based on a qualitative assessment of tumour morphology and signal
intensity in each of the available CMR sequences (Table 1).5–9 Evalu-
ation of tumour morphology included tumour location, shape and
mobility, tumour border definition and/or tissue infiltration, and the
presence of pericardial effusion. The tissue composition of a lesion
was estimated based on the signal characteristics and qualitatively
scored as homogenous or heterogeneous. In addition, in each
sequence tumour signal intensity was assessed qualitatively as hypo-,
iso-, or hyperintense with reference to the normal myocardium.
Finally, tumour vascularization and the presence of interstitial fibrosis
or extensive acellular areas within the mass were qualitatively scored
as present or absent on first-pass perfusion imaging and delayed
contrast-enhanced imaging, respectively.
Statistical analysis and reporting
Statistical analysis was performed using SPSS 15.0 (SPSS Inc., Chicago,
IL, USA). Categorical data are summarized as frequencies and percen-
tages; continuous variables are expressed as mean+ SD or as median
Figure 1 Cardiac magnetic resonance-based diagnosis, patient management, and available data. Of note, the blinded cardiac magnetic reson-
ance assessment was not different from the initial reading on which the subsequent clinical considerations and the final patient management
were based. ‘Operability’: cardiac magnetic resonance-based judgement of haemodynamic relevance, malignancy, dissemination, and operability
of the mass as part of the clinical decision process. Bottom level displays data available for analysis as a result of this process. Asterisk denotes
the histological specimens available.
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Table 1 Typical features of most common cardiac tumours and masses in their classical presentation
Preferential
location
Morphological
characteristics
Pericardial
effusion*
Signal
composition
T2-weighted
TSE
T1-weighted
TSE
Contrast
enhancement
Perfusion
CE-SR-GRE
Benign tumours
Myxoma IAS intracavitary Lobular or frond-like,
pedunculated, mobile
No Heterogeneous  ↔ +/2 ? (2)
Lipoma Any chamber, endo/
myocard
Smooth, broad based
intracavitary+mobile
No Homogenous  FS  FS 2 ? (2)
Fibroelastoma Valves Small, round,+mobile No Homogenous ↔  ↔ + ? (2)
Haemangioma Any chamber, endo/
myocard
Lobular+mobile Infrequent Heterogeneous  ↔ + ? (+)
Fibroma Ventricular
myocard
Smooth/encapsulated,
immobile
No Homogenous  ↔  2 (outer rim +) ? (2)
Rhabdomyoma Ventricular
myocard
Smooth, sometimes multiple No Homogenous ↔ ↔  As myocardium ?
Malignant tumours
Rhabdomyosarcoma Myocard Lobular, invasive Possible Heterogeneous ↔ ↔ +/(2) ? (+)
Liposarcoma Atrium or myocard Lobular, invasive Possible Heterogeneous ↔ ↔  FS +/(2) ? (+)
Sarcoma: angio/leio/
osteo-
Atrium/veins Sessile, lobular, invasive,
obstructive
Common Heterogeneous  ↔ + ? (+)
Lymphoma Myo/pericard Lobular, multiple lesions Common Heterogeneous ↔  ↔ + ? (+)
Metastases Any chamber
variable
Often smooth, sometimes
multiple
Common Heterogeneous  ↔ +/(2) +
Non-neoplastic
Thrombus: fresh Infarct area, left
auricle
Adjacent scar No Homogenous ↔  ↔  2 2
Thrombus: old Infarct area, left
auricle
Adjacent scar No Homogenous  ↔  ↔ 2 2/(+)
Benign cysts Para-/pericard Smooth, circumscribed liquid
(homogeneous)
No Homogenous   2 2
Variants (muscular) Wall contact As normal variants No Homogenous ↔ ↔ + +
Based on refs,5–9 asterisk indicates the absence of heart failure. FS indicates that the high signal can be suppressed by fat-specific saturation prepulses. ? indicates currently unknown; as expected from histology.
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(inter-quartile range) as appropriate. A two-sided P-value of ,0.05
was considered as statistically significant. Differences in CMR charac-
teristics between malignant and benign masses were compared by
Fisher’s exact test. Survival for patients with tumours stratified
by CMR as malignant, benign, or normal variants was compared by
log-rank analysis on the Kaplan–Meier survival curves.
Results
The final study population comprised 41 patients (21 men, mean
age 61+14y), presenting with a mass alleged in echocardiography
(n ¼ 39) or incidentally found on a chest CT (n ¼ 2). Presenting
symptoms were heart failure (n ¼ 6), stroke (n ¼ 4), syncope
(n ¼ 3), acute coronary syndrome (n ¼ 2), and pulmonary embo-
lism (n ¼ 1). In the remaining patients, the mass was revealed acci-
dentally in the context of tumour staging (n ¼ 4) or during elective
work-up for weight loss, dyspnoea, hypertension, angina, or
arrhythmias. The referral technique postulated the suspected
mass to be neoplastic in 23 (56%) patients (malignant/benign: 7/
15), non-neoplastic in four (10%), and remained uncertain about
the nature of the lesion in the remaining 15 (36%) patients. Four-
teen patients (34%) had a prior history of non-cardiac malignancy,
(haematological malignancy n ¼ 4, bronchus carcinoma n ¼ 3,
breast cancer n ¼ 2, and oropharynx, ovarium, prostate, or semi-
noma each in n ¼ 1), with documentation of non-cardiac meta-
static spreading before CMR in four.
Cardiac magnetic resonance-based
stratification and patient management
On the basis of the consensus reading of the CMR images, the sus-
pected mass was identified and classified as neoplastic in 23 (56%)
and as non-neoplastic or absent in 17 (42%) of the 41 patients. In
one patient with a well-perfused and enhancing intramural left
atrial mass, the initial CMR was equivocal on the presence of a
malignancy or an inflammatory pseudotumour (Figure 1). After
serial CMR and clinical assessments under immunosuppressive
therapy, vasculitis involving the atrial wall was eventually estab-
lished as diagnosis. Table 2 lists the main findings in patients with
a CMR diagnosis of cardiac neoplasm and/or histological data for
comparison. Eight tumours were judged by the CMR experts to
be malignant, 14 benign, and in one patient, consensus on the
malignancy could not be reached. In the remaining patients, CMR
either concluded on the presence of thrombus (n ¼ 2), established
the suspected masses as anatomical variants (atypically localized
epicardial fat, lipomatous hypertrophy of the interatrial septum,
prominent atrial cristae, and localized ventricular hypertrophy,
each in 2), or could not detect any mass at all (n ¼ 7). Cardiac
magnetic resonance was the ultimate imaging technique used for
tumour characterization in all patients.
A surgical procedure was proposed as final therapy and histo-
logical data were obtained in 18 of the 23 patients with neoplasm,
whereas in five, surgery was declined because of evidence for dis-
seminated cancer (n ¼ 3) or for critically localized, benign tumours
not justifying a high-risk intervention (n ¼ 2). The latter five
patients with and the remaining 18 patients without a neoplastic
lesion diagnosed by CMR were managed conservatively with docu-
mentation of clinical events (Figures 1 and 2). Histological
information on the nature of the suspected mass in this group
thus failed, except for two patients who died and underwent
autopsy within 40 days of the initial CMR.
Cardiac magnetic resonance findings
compared with histology
In 16 out of 20 cases (80%) with available histopathological data,
the CMR features in adjunct to the referral information permitted
to classify the masses correctly as ‘malignant neoplasm’, ‘benign
neoplasm’, or ‘no neoplasm’ (Table 2). Cardiac magnetic resonance
experts misclassified two non-neoplastic masses as benign neo-
plasm and inversely failed to detect a small (8 × 8 mm) fibroelas-
toma, yielding an accuracy of 17 of 20 (85%) to classify masses
correctly as neoplasm or not. One metastasis with extensive
myxoid degeneration on gross pathological examination was mis-
classified as a benign myxoma. Thus, in dichotomizing masses as
benign in nature or not, CMR was accurate in 19 of 20 (95%) of
all cases. Table 3 summarizes the most useful CMR criteria in the
distinction between malignant and benign lesions.
Tissue and/or tumour characteristics on
cardiac magnetic resonance
Individual signal characteristics of the alleged masses were highly
variable. An integrative approach allowing for the interpretation
of signal patterns (Table 1) enabled a certain level of virtual histo-
logical differentiation that proved helpful in selected clinical scen-
arios. Some typical patterns are described here.
Normal variants and non-neoplastic masses
In most (10/15, 67%) of the cases where CMR excluded masses (n
¼ 7) or demonstrated anatomic variants that had been interpreted
as a possible mass (n ¼ 8), focal wall thickening or extensive epi-
cardial tissue masses had evoked doubt about the presence of
an intramural or epicardial tumour. Cardiac magnetic resonance
diagnosis was based on the absence of soft tissue contrast in all
driven sequences or on the demonstration of excessive fat depo-
sition. Two small valvular lesions irrefutably demonstrated by
echocardiography, of which one was histologically confirmed as
fibroelastoma, were nevertheless missed. Thrombi (n ¼ 2) were
diagnosed based on the presence of an intracavitary mass
without perfusion and late enhancement, but typically adjacent
to the myocardium displaying delayed enhancement.10 Figure 3
provides an example in a patient referred with suspicion of
apical tumour or hypertrophy.
Lipoma and lipomatous septal hypertrophy
Typical for these fatty masses was a homogeneous and hyperin-
tense signal in cine and spin echo sequences, behaving similar to
subcutaneous fat in all sequences and displaying signal loss after
fat saturation prepulses (Figure 4). Whereas the lipoma (n ¼ 1)
was well defined and partially intramural, lipomatous hypertrophy
rather presented as diffuse thickening of the interatrial septum and
adjacent posterior right atrial wall, with sparing of the fossa ovalis.
Echocardiography remained equivocal about the nature of the
mass in all cases, erroneously suggesting metastatic infiltration in
one patient (Case 24).
S. Fussen et al.1554
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Table 2 Cases with cardiac magnetic resonance diagnosis of neoplasm and/or histological data
Case no. Sex Age Prior malignancy Echo or CT diagnosis CMR diagnosis Histology
Neoplasm diagnosed by CMR, operative treatment
1a F 61 Ovarium, M+ M, cystic: meta M, cystic: meta M, meta
2a M 65 Lung, M+ E, meta/infectious M, meta M, meta
3a M 55 inv.haemangiom M, nonprim. card. M, nonprim. card M, haemangiosarcoma
4a M 44 Synovia, M+ M, meta B, myxoma M, meta (myxoid)
5 F 57 Breast E, myxoma/meta B, myxoma B, myxoma
6a F 75 Mult. Myel. B, myxoma B, myxoma B, myxoma
7 F 78 Mult. Myel. B, myxoma B, myxoma B, myxoma
8 M 63 Lung E, myxoma/meta B, myxoma B, myxoma
9a F 42 — E, infectious/other M, sarcoma M, angiosarcoma
10 M 45 — M, nonprim. card. M, nonprim. card. M, malignant thymoma
11a M 68 — M, nonprim. card. M, nonprim. card. M, undiff. sarcoma
12 F 58 — B, myxoma B, myxoma B, myxoma
13 F 70 — B, myxoma B, myxoma B, myxoma
14 M 70 — E, myxoma/meta B, myxoma B, myxoma
15 M 61 — B, myxoma B, myxoma B, myxoma
16 F 73 — E, unclear mass B, fibroma NN, caseus calcification
17 F 50 — B, myxoma B, myxoma NN, thrombus
18 M 62 — B, myxoma B, myxoma B, myxoma
Neoplasm diagnosed by CMR, conservative management
19a F 63 Mult. Myel, M+ M, meta M, sarcoma NA
20a M 82 Lung E, meta/myxoma E, meta/myxoma NA
21a F 70 Breast E, mass present? M, meta NA
22 F 86 — B, myxoma B, haemangioma NA
23 M 44 — E, unclear mass B, lipoma NA
Neoplasm excluded by CMR, conservative management, autopsy data available
24a F 61 Pharynx, M+ M, meta NN, IASH NN, IASH
25a F 78 — NN, fibroelastoma E, no mass seenb NN, fibroelastomac
Cases grouped according to the presence of a tumour diagnosed by CMR and/or availability of histological data, and by the presence or absence of prior malignancies. M+, known
extracardiac metastasis at time of referral; inv.haemangiom, invasive haemangioma; Mult. Myel., multiple myeloma; meta, metastasis; nonprim. card., non-primarily cardiac
malignancy of mesenchymal or lymphoid origin; IASH, lipomatous hypertrophy of the interatrial septum; caseus calcification of the mitral annulus; E, equivocal; NN,
non-neoplastic; B, benign; M, malignant; NA, not available.
aDied during follow-up.
bNo mass seen considered as benign condition.
cFibroelastoma is generally not regarded as a neoplasm.
Figure 2 Diagnoses and outcome in conservatively managed patients. Asterisk indicates the fibroelastoma (8 × 8mm) resected on the
occasion of combined coronary artery and valve surgery; patient died from post-operative multi-organ failure.
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Table 3 Distinctive characteristics of benign and malignant masses
Benign lesions (n 5 13) Malignant tumours (n 5 7) P-value
Previous cancer
No/yes/metastatic 8/4/1 3/1/3 0.31
Localization
RA 0 3 ,0.01
LA 5 0
IAS-left/right/mid 6/1/1 1a/0/0
Pericard/paracardial 0/0 1/2
Invasiveness
No/invasive/compressive 11/2/0 1/3/3 ,0.01
Pericardial effusion
Yes/no 0/13 4/3 ,0.01
Composition
Homogenous/inhomogeneous 3/10 1/6 1.0
Signal intensity T1
Hypo-/iso-/hyperintense 1/9/2 0/2/5 0.05
Signal intensity T2
Hypo-/iso-/hyperintense 1/3/7 0/2/4 1.0
Perfusion
Detected/none 1/8 (n ¼ 9) 3/1 (n ¼ 4) 0.05
Contrast enhancement
None/weak/abundant 8/1/3b (n ¼ 12) 1/2/3 (n ¼ 6) 0.16
aAs judged on CMR, intra-operatively, the tumour proved to be attached to the LA roof, not the IAS.
b9/1/2, P ¼ 0.07 after accounting for fat as the reason for the high signal on LGE-imaging in lipomatous hypertrophy of the IAS.
Figure 3 Apical thrombus adjacent to endocardial fibrosis in a patient with vasculitis. Being indistinguishable from the normal myocardium in
cine imaging (A) and T1-weighted turbo spin echo sequences (B), the mass is hypointense in fat-saturated T2-weighted imaging and delineated
by a hyperintense rim suggesting oedema (C). Contrary to the myocardium, signal intensity in the mass remains unchanged between the left
ventricular phase (D) and the myocardial phase (E) of contrast passage, indicating poor or absent mass perfusion. Accordingly, there is no
delayed uptake of contrast within the mass a rim of enhancement compatible with endocardial fibrosis is seen (F ).
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Myxoma
All histologically confirmed myxomas (n ¼ 9) were heterogeneous
in cine imaging, compatiblewith regional differences in cellularity and
extensive myxoid stroma and with occasional focal necrosis and
haemorrhage. Myxomas were typically hyperintense in T2-TSE
and isointense in T1-TSE. Signal enhancement during first-pass per-
fusion and delayed enhancement was detected in 16 and 40% of the
cases, respectively (Figure 5). Myxomas were pedunculated, mobile,
and attached at the left (78%) or right (11%) interatrial septum. One
myxoma (11%) grew in close contact with a pulmonary vein ostium.
A thrombus mistaken for myxoma (Case 17) differed from the
common pattern by a similar atypical localization (pulmonary vein
ostium) and low signal in T2-TSE. A left atrial metastasis with exten-
sive myxoid degeneration at histology had typical signal features of
myxoma (Case 4). Nevertheless, clinical suspicion of metastasis
was raised by concomitant visualization of pulmonary metastasis.
Malignant tumours (primary and metastasis)
Malignant tumours typically (≥85%) presented on CMR as broad-
based bulky masses with invasive or compressive growth and signal
heterogeneity. Although not a universal finding, pericardial effusion
was a common and highly specific feature (Table 3). Sarcomas (n ¼
3) were hyperintense in T2-TSE, had signal heterogeneity in mul-
tiple sequences, and heterogeneous uptake of contrast. All metas-
tases (n ¼ 4) were diagnosed in patients with previously
demonstrated extracardiac metastatic spreading. Signal character-
istics and contrast enhancement were variable and inconsistent.
Compared with the referral technique, CMR diagnosed a
primary cardiac sarcoma in a young woman with presumptive diag-
nosis of an inflammatory mass (Figure 6) and better documented
infiltration and local spreading in all cases, aiding operative
planning.
Cardiac magnetic resonance findings
compared with clinical follow-up
Overall, and considered independently of therapeutic manage-
ment, 13 deaths occurred over a median observation period of
705 (303–1472) days. All but one of the patients with a malignant
tumour diagnosed on CMR died; on average within 377 (76–819)
days. By the Kaplan–Meier analysis, mortality in patients diagnosed
by CMR with a benign neoplasm [2/14, within 1160 (408–1650)
Figure 4 Septal lipoma. The signal intensity of the intramural tumour is homogeneous and behaves similar to subcutaneous fat in all
sequences: the high signal in T1-weighted turbo spin echo sequences (A) is suppressed after a fat-specific saturation pulse (B). There is no
detectable contrast uptake on fat-saturated T1-weighted turbo spin echo sequences repeated 10 min after gadolinium administration (C).
Figure 5 Perfusion and late enhancement study of a myxoma. A large mass with attachment to the right-sided interatrial septum is identified.
On first-pass perfusion images taken during the ventricular (A) and myocardial perfusion phase (B), no noticeable perfusion is discerned.
Delayed gadolinium enhancement of the tumour is also absent (C ). The diagnosis of myxoma was confirmed at histology.
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days] was significantly lower than that in those diagnosed with a
malignant tumour (P, 0.01) and did not differ from mortality in
patients where CMR had concluded that a cardiac mass was
either absent or non-neoplastic [3/18 within 745 (286–1492)
days]. Of importance, of these five patients dying despite the diag-
nosis of a benign condition, only one patient (Case 4) was misclas-
sified by CMR, whereas in four, the histological (Cases 6, 24, and
25) or clinical (relapsing empyema) data excluded the suspected
mass as cause of death. As such, when considered from the per-
spective of CMR-guided therapy management (‘intention to
treat’), no tumour-related deaths occurred in conservatively
managed patients other than in those receiving palliative care
(Figure 2). Inversely, two patients without neoplasm were sub-
jected to surgery after an erroneous CMR diagnosis of a benign
neoplasm.
Discussion
The present study showed that a comprehensive CMR evaluation
of tumour morphology, tissue composition, and perfusion in con-
junction with information on tumour spread and operability can
adequately direct patients to the appropriate therapeutic strategy.
In particular, CMR excelled in its capacity to risk stratify patients by
confidently excluding masses or reclassifying them as anatomical
variants and by distinguishing benign from malignant processes.
Although enhanced soft tissue contrast in various sequences
increased depiction, delineation, and enhanced stratification of
the masses compared with echocardiography, CMR faced limit-
ations in depicting small valvular lesions and in tissue characteriz-
ation at the histological level.
With a incidence of 0.03% (primary tumours) to 2.0% (all
tumours) in autopsy series11–13 and 0.15% in echocardiographic
series,14 cardiac tumours are rare entities in clinical cardiology
that pose particular challenges to diagnostic cardiac imaging.
Cardiac tumours have a broad differential diagnosis and need to
be distinguished from non-neoplastic masses. In addition, treat-
ment is significantly directed by symptoms, haemodynamic,
embolic, or arrhythmic implications, and by neoplastic nature,
type, dissemination, or operability of the mass.1–3,15 Optimal
tumour characterization for clinical management therefore
includes information on local tumour topology and invasiveness,
and at best delivers some degree of tissue characterization. Being
Figure 6 Primary cardiac sarcoma. Short-axis cine imaging (A), T2-weighted turbo spin echo sequences (B), and T1-weighted turbo spin echo
sequences before (C) and after contrast (D), demonstrating an invasive right atrial tumour with inhomogeneous composition and extensive
pericardial effusion (asterisks). The tumour displays areas where signal is lower in T2-weighted turbo spin echo sequences, higher in
T1-weighted turbo spin echo sequences, and less enhancement after contrast is seen (arrowheads), compatible with intratumoral haemorrhage.
The intermediate signal of the pericardial effusion in the T1-weighted turbo spin echo sequences suggests haemorrhagic effusion. An angiosar-
coma was diagnosed.
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non-invasive, cost-effective, quick, and widely available, echocar-
diography is usually employed as first-line imaging modality.15,16
In fact, many masses—in the present study up to 50%—are coin-
cidently detected during examinations for unrelated conditions.
This technique was also found to have a primary diagnostic role
in the detection of valvular lesions and to allow for a relatively con-
fident diagnosis of typically localized myxomas. Incomplete or
inadequate acoustic windows and rather poor tissue contrast
restrict the capacity of echocardiography to properly evaluate
and delineate peri- and paracardiac lesions17 and to adequately
differentiate among various tissue types.18 The unrestricted field
of view combined with superior soft tissue and blood pool con-
trast in various unenhanced CMR sequences renders distinct
advantages under such circumstances.4,5 Contrast agents further
enhance detection and delineation of masses when distinction of
intramural tumours from the normal myocardium still remains
equivocal and are invaluable in the detection of intracavitary
thrombi.8,10,18,19 Thus, paracardiac, metastatic, and infiltrative pro-
cesses may be assessed more readily or can inversely be excluded
with more confidence by CMR. Indeed, referrals because of
ambivalent echocardiographic findings comprised .30% of the
CMR examinations and mostly related to intramural, retrocardial,
or pericardial masses that could be confidently excluded by sub-
sequent CMR.20,21 In a study by Winkler and Higgins21 including
34 patients followed for up to 2 years, CMR could exclude or
reclassify cardiac masses to anatomic variants or other abnormal-
ities in up to 58 and 20% of the masses suspected on echocardio-
graphy, respectively. The excellent outcome under long-term
conservative treatment observed in our study provides evidence
that refraining from surgical exploration or intervention in such
patients is both justified and safe. In the case of suspicious small
valvular lesions like fibroelastoma, CMR may however perform
suboptimally22 and rather an echocardiography-guided manage-
ment, although often not surgical in nature, appears warranted.
Only a limited number of studies have systematically examined
the value of various pulse sequences and/or contrast enhancement
techniques in differentiating cardiac masses based on their tissue
characteristics.6–8 In the differentiation between malignant and
benign lesions, the present data and a previous study by Hoffmann
et al.7 indicated an overall accuracy of 90–95% for an integrative
CMR assessment of morphological features and signal character-
istics. Yet, no single CMR feature was both highly specific and
highly sensitive in the differentiation between benign or malignant
cardiac and paracardiac masses. In particular, morphological fea-
tures, such as right-sided or paracardiac location, invasive or com-
pressive growth patterns and presence of pericardial effusion,
emerged as single predictors for malignancy,7,23 whereas individual
signal characteristics had little predictive value per se. As illustrated
in Table 1, this is partially explained by the high variability of single
T1 and T2 signal characteristics among the various benign and
malignant masses, which used in isolation consequently provide
little information on the biological nature of the tumour. Never-
theless, confident CMR characterization is possible for some
tumours and masses homogeneously composed of a tissue type
with a more or less characteristic morphological and signal ‘finger-
print’, such as fat and lipomas, fibrosis and fibromas, and pericardial
cysts.5,7,8 Fat, for example, has very constant T1 and T2 signal
properties that can be suppressed in a selective manner by fat-
specific saturation prepulses. In the present population, these
unique signal properties allowed for a confident risk stratification
and conservative management of many patients with benign fatty
masses. As opposed to homogeneous tissue characteristics in
the above-mentioned conditions, a heterogeneous signal compo-
sition of the tissue indicative of focal haemorrhage, necrosis, calci-
fication, or regional myxoid degeneration has been reported as a
sensitive feature of malignancy.7,8 It has, however, also been con-
sistently reported in myxomas7,24 and accordingly did not
emerge as a distinctive feature in the present study. On the
same grounds, post-contrast enhancement has been proposed as
a feature of malignancy.7,8,23 Late enhancement of myxoid
stroma or necrotic areas within myxomas is, however, also
rather common, amounting up to 40% in our study.6–8 Intense,
inhomogeneous enhancement early after contrast is also seen in
benign cardiac haemangiomas.25 Perfusion imaging aims at depict-
ing tumour perfusion and capillary density by assessing the contrast
wash-in dynamics at first passage. Fibroelastoma and thrombus are
principally avascular masses and many benign tumours (e.g.
fibroma, lipoma) are rather sparsely vascularized compared with
the faster growing malignant tumours, with the noticeable excep-
tion of haemangioma.1 The importance of first-pass perfusion
imaging in tumour characterization has not been investigated
before. In the subset of patients subjected to this technique, malig-
nant lesions tended to display noticeable perfusion more fre-
quently. Contrary to late enhancement, signal increase in
first-pass contrast passage was rare in myxomas (16%). This poten-
tial benefit over late enhancement imaging requires confirmation in
larger studies.
Finally, integration of imaging data with epidemiological prob-
ability and clinical data is an integral part of tumour stratification
and clinical decision-making in daily practice. All patients with
cardiac metastasis in our study had a history of extracardiac meta-
static disease. On the other hand, CMR confidently differentiated
lipomatous hypertrophy from metastatic infiltration and accurately
diagnosed a few myxomas in cancer patients, while identifying
cardiac infiltration in others. This highlights that CMR may
convey independent information for differential diagnosis and
operative planning in many patients.7,20 Most importantly, in
patients managed conservatively based on the CMR diagnosis, no
tumour-related deaths occurred other than in those receiving pal-
liative care because of documented metastatic disease. As such,
from the perspective of CMR-guided therapy management (‘inten-
tion to treat’), CMR was found accurate.
Limitations
It should be acknowledged that the eventual study outcome rep-
resents the result of a staged approach in which echocardiography
was the gatekeeper to most of the CMR examinations. In the
absence of a comparison free of potential referral bias, the additive
value of CMR to echocardiography and clinical assessment remains
difficult to establish. As either individual technique was found to
yield specific limitations and to have some complementary
assets, such combined approach may currently remain warranted.
Another acknowledged limitation of the study is its retrospective
design; despite all efforts to improve the consistency in CMR
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interpretation by pre-specified scoring systems and review sessions
blinded from other than the referral information, this inherently
carries the risk of somewhat overestimating the favourable
results for CMR. With technological advances, some typical
CMR parameters (e.g. late enhancement and perfusion) have
become readily feasible by echocardiography and/or CT and
need to be explored in the future. More in general, also for
most of the contemporary CMR sequences and for contrast appli-
cations in particular, tumour characteristics reported in previous
studies remain scattered and scarce. Although our study adds
more data to this field and is encouraging enough to endorse
CMR as a decisive imaging modality in this orphan disease, pro-
spective multicentre registries and/or studies26 should follow to
underscore the results.
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